Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) climbed nearly 2% in after-hours trading Monday after the U.S.
Maxim’s Jason McCarthy believes Vertex could “unlock” over 90% of the cystic fibrosis market as time passes.
Drug maker Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported a beat and raise this quarter both on the top and bottom-line for Q3 2017. During …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the FDA has approved KALYDECO® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) …
J.P.
Gilead’s FDA-Approved Drug Still Faces an Uphill Battle in HCV Ring Gilead Sciences, Inc. (NASDAQ:GILD) just scored a green light from the FDA …
Many investors hope to win big on biotech stocks as shares can skyrocket when there is good news. Maxim analysts explain why there …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) investors are overwhelmingly excited this afternoon after the drug maker announced positive data from Phase 1 and Phase 2 …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported consolidated financial results for the quarter ended March 31, 2017. Vertex also reiterated guidance for total 2017 ORKAMBI® (lumacaftor/ivacaftor) revenues …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have excited investors with key clinical moves forward for the firms, between VRTX’s double …
